Drugs / SPH4336
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT05944224 | Oct 2023 → May 2026 overdue | cancer | Shanghai Pharmaceuticals Holding Co., Ltd | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05905614 | Nov 2020 → Oct 2023 | cancer | Shanghai Pharmaceuticals Holding Co., Ltd | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT05872347 | Sep 2023 → Dec 2026 expected | metastatic malignant neoplasm in the brain | Shanghai Pharmaceuticals Holding Co., Ltd | Recruiting | No outcome recorded |
| Phase 2 | NCT05580588 | Aug 2023 → Oct 2024 | dedifferentiated liposarcoma | Shanghai Pharma Biotherapeutics USA Inc. | Terminated | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT05860465 | Sep 2023 → Dec 2026 expected | breast cancer | Shanghai Pharmaceuticals Holding Co., Ltd | Recruiting | No outcome recorded |
| Phase 2/3 | NCT05744687 | Apr 2023 → May 2026 overdue | breast cancer | Shanghai Pharmaceuticals Holding Co., Ltd | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SPH4336 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05860465 ↗ |
| Action | Inhibit | “CDK4/6 inhibitor” NCT05580588 ↗ |
| Route | Oral | “will be administered orally once each day” NCT05580588 ↗ |
| Target | CDK4 | “CDK4/6 inhibitor” NCT05580588 ↗ |